Amgen

Public profile

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics.

Run byGeorge Rathmann

📖 Wikipedia 📈 AMGN

▸✏️ Suggest a correction

Spot something wrong? Edit the fields — changes go live immediately and are logged for audit.

Wikipedia URLChanging the Wikipedia URL re-triggers full enrichment (bio + image auto-fill).Profile image URLBio (English)Bio (Hebrew)

📡 Recent posts· 0

No posts pulled in yet. Add where this person/organization posts below, and the platform starts pulling in new posts.

Where they post

No outlets set yet.

📊 FinancialAMGN · NASDAQ

$344.72

+7.12 · +2.11%

Prev close: $337.60

Mkt cap$182.2B

Open$337.65

High$345.11

Low$337.60

% from low2.11%

Loading chart…

▾ 📰 Recent news8 headlines · AMGN

Abbvie acquiring Apogee for $10.9B, Coca-Cola vs. IRS in appeals court
Yahoo· <1h ago

Yahoo Finance Senior Reporter Brooke DiPalma joins Josh Lipton in highlighting the day's biggest stories and stock moves, including AbbVie's (ABBV) $10.9 billion acquisition of Apogee Therapeutics (APGE) and Coca-Cola…
Which dow jones stocks are moving on Monday?
ChartMill· 1h ago

Join us in exploring the top gainers and losers within the dow jones index one hour before the close of the markets on Monday as we examine the latest happenings in today's session.
Stock Market Today: Dow Up, Big Tech Falls Amid Rate Hike Forecasts; These AI Stocks Test Entries (Live Coverage)
Yahoo· 2h ago

The Dow Jones index rises as Treasury Secretary Scott Bessent makes an Iran move. SpaceX skids but some AI stocks test buy points.
Top dow jones movers in Monday's session
ChartMill· 4h ago

Uncover the latest developments among dow jones stocks in today's session. Stay tuned to the dow jones index's top gainers and losers on Monday.
Stock Market Today: Dow Up As Bessent Makes Iran Move; Microsoft Falls After Nadella Says This (Live Coverage)
Yahoo· 5h ago

The Dow Jones index rises as Treasury Secretary Scott Bessent makes an Iran move. Microsoft falls on the stock market today. SpaceX skids.
Dow Jones opens higher but Nasdaq flat as hawkish Fed still looms
Yahoo· 8h ago

9.55am: Dow up but Nasdaq flat US stocks were showing a familiar split in opening trades, with the Dow Jones opening up 0.5% as investors rotate into cyclical and defensive blue chips including JPMorgan, Goldman Sachs…
Less Volume, More Premium: Post-Ozempic Economics Are Killing The Quantity Model
Benzinga· 13h ago

As millions take GLP-1 drugs, packaged food giants face declining volumes while protein brands and specialty grocers win.
Amgen vs. NovoCure: Which Health Care Stock Is a Better Buy in 2026?
Yahoo· 3d ago

Amgen posts strong profits and cash flow, while NovoCure pursues growth with a direct-to-patient cancer therapy model and leaner balance sheet.

▾ 🧱 Sum of the parts7 rows · est. $216B total

Name	Type	% stake	Paid	Annual rev	Now worth	×% our share	Note
Biopharmaceuticals	🧩 segment	100.0%	—	$30.0B	$170.0B	$170.0B	Core business encompassing research, development, manufacturing, and commercialization of human therapeutics.
Other	🧩 segment	100.0%	—	—	—	—	holdings not assigned to a reported segment
Deciphera Pharmaceuticals (select assets) · acq. 2024	🏢 subsidiary	100.0%	$0.4B	—	$0.4B	$0.4B	Acquired select assets, including the rights to QINLOCK (ripretinib) in Europe, for gastrointestinal stromal tumor.(acquisition price)
Five Prime Therapeutics · acq. 2021	🏢 subsidiary	100.0%	$1.9B	—	$2.0B	$2.0B	Acquired for its oncology asset, bemarituzumab.(acquisition price)
Horizon Therapeutics · acq. 2023	🏢 subsidiary	100.0%	$27.8B	—	$28.0B	$28.0B	Acquired to expand Amgen's rare disease and inflammation portfolio.(acquisition price)
Otezla (from Celgene/BMS) · acq. 2019	🏢 subsidiary	100.0%	$13.4B	—	$15.0B	$15.0B	Acquired the global rights to Otezla (apremilast) for psoriasis and psoriatic arthritis.(acquisition price)
Teneobio · acq. 2021	🏢 subsidiary	100.0%	$0.9B	—	$1.0B	$1.0B	Acquired for its bispecific and multispecific antibody technologies.(acquisition price)